Medicinal chemistry of indolylglyoxylamide TSPO high affinity ligands with anxiolytic-like effects

Current Topics in Medicinal Chemistry

Volumn 12, Issue 4, 2012, Pages 333-351

  Simorini, Francesca ^a   Marini, Anna Maria ^a   Taliani, Sabrina ^a   la Motta, Concettina ^a   Salerno, Silvia ^a   Pugliesi, Isabella ^a   da Settimo, Federico ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

2 phenylindolylglyoxylamides; Anxiolytic activity; Binding affinity; Neurosteroids; Pregnenolone; SARs; Translocator protein (TSPO); TSPO ligands

Indexed keywords

2 ARYL 8 OXODIHYDROPURINE; 2 PHENYLIMIDAZOPYRIDINE; 3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID A RECEPTOR; 7 CHLORO 2 (3 PYRIDYL) ALPHA TETRALONE; ALPIDEM; ALPRAZOLAM; ANXIOLYTIC AGENT; ARYLOXYANILIDE; BENZODIAZEPINE RECEPTOR; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; DIAZEPAM; EMAPUNIL; FLUMAZENIL; INDOLEACETAMIDE; MITOCHONDRIAL PROTEIN; MITOCHONDRIAL TRANSLOCATOR PROTEIN; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; N,N DIALKYLINDOL 3 YLGLYOXYLAMIDE DERIVATIVE; PREGNENOLONE; RO 54864; TRILOSTANE; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT ANION CHANNEL; ZOLPIDEM;

ABSENCE OF SIDE EFFECTS; ANXIETY DISORDER; APOPTOSIS; BINDING AFFINITY; BIOTRANSFORMATION; COMPETITIVE INHIBITION; DIAGNOSTIC IMAGING; DRUG DESIGN; GENERALIZED ANXIETY DISORDER; HUMAN; HYDROPHOBICITY; LIGAND BINDING; LIPOPHILICITY; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PANIC; POINT MUTATION; POSTTRAUMATIC STRESS DISORDER; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR AFFINITY; REVIEW; SITE DIRECTED MUTAGENESIS; STEROIDOGENESIS; STRUCTURE ACTIVITY RELATION; TRANQUILIZING ACTIVITY;

AMIDES; ANIMALS; ANTI-ANXIETY AGENTS; BINDING SITES; BRAIN; GABA-A RECEPTOR AGONISTS; GABA-A RECEPTOR ANTAGONISTS; GLYOXYLATES; HUMANS; INDOLES; LIGANDS; NEUROTRANSMITTER AGENTS; PROTEIN BINDING; PROTEIN SUBUNITS; RECEPTORS, GABA; RECEPTORS, GABA-A; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84856479937     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612799078766     Document Type: Review

References (107)

1. Costa, E.; Guidotti, A. Benzodiazepine on trial: a research strategy for their rehabilitation. Trends Pharmacol. Sci., 1996, 17, 192-200.
2. A/Bz receptor subtypes as targets for selective drugs. Curr. Med. Chem., 2007, 14, 2680-2701.
3. Taliani, S.; Da Settimo, F.; Da Pozzo, E.; Chelli, B.; Martini, C. Translocator Protein Ligands as Promising Therapeutic Tools for Anxiety Disorders. Curr. Med. Chem., 2009, 16 (26), 3359-3380.
4. 3H]diazepam binding. Proc. Natl. Acad. Sci. USA, 1977, 74, 3805-3809.
5. Gavish, M.; Bachman, I.; Shoukrun, R.; Katz, Y.; Veenman, L.; Weisinger, G.; Weizman, A. Enigma of the peripheral benzodiazepine receptor. Pharmacol. Rev., 1999, 51, 619-640.
6. Papadopoulous, V. Peripheral-type benzodiazepine/diazepam binding inhibitor receptor: biological role in steroidogenic cell function. Endocr. Rev., 1993, 14, 222-240.
7. Culty, M.; Li, H.; Boujrad, N.; Amri, H.; Vidic, B.; Bernassau, J.M.; Reversat, J.L.; Papadopoulos, V. In vitro studies on the role of the peripheral-type benzodiazepine receptor in steroidogenesis. J. Steroid Biochem. Mol. Biol., 1999, 69, 123-130.
8. Papadopoulos, V. Peripheral benzodiazepine receptor: structure and function in health disease. Ann. Pharm. Fr., 2003, 61, 30-50.
9. Casellas, P.; Galiegue, S.; Basile, A.S. Peripheral benzodiazepine receptors and mitochondrial function. Neurochem. Int., 2002, 40, 475-486.
10. Lacapère, J-J; Papadopoulos, V. Peripheral-type benzodiazepine receptor: structure and function of a cholesterol-binding protein in steroid and bile acid biosynthesis. Steroids, 2003, 68, 569-585.
11. Veenman, L.; Papadopoulos, V.; Gavish, M. Channel-like functions of the 18-kDa translocator protein (TSPO): regulation of apoptosis and steroidogenesis as part of the host-defence response. Curr. Pharm. Des., 2007, 13, 2385-2405.
12. Papadopoulos, V.; Baraldi, M.; Guilarte, T.R.; Knudsen, T.B.; Lacapère, J.-J.; Lindemann, P.; Norenberg, M.D.; Nutt, D.; Weizman, A.; Zhang, M-R.; Gavish, M. Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci., 2006, 27, 402-409.
13. Syapin, P.J.; Skolnick, P. Characterization of benzodiazepine binding sites in cultured cells of neural origin. J. Neurochem., 1979, 32, 1047-1051.
14. Scarf, A.M.; Ittner, L.M.; Kassiou, M. The translocator protein (18 kDa): central nervous system disease and drug design. J. Med. Chem., 2009, 52 (3), 581-592.
15. Anholt, R.R.; Pedersen, P.L.; De Souza, E.B.; Snyder, S.H. The peripheral-type benzodiazepine receptor. Localization to the mitochondrial outer membrane. J. Biol. Chem., 1986, 261, 576-583.
16. Antkiewicz-Michaluk, L.; Guidotti, A.; Krueger, K.E. Molecular characterization and mitochondrial density of a recognition site for peripheral-type benzodiazepine ligands. Mol. Pharmacol., 1988, 34, 272-278.
17. Veenman, L.; Gavish, M. The peripheral-type benzodiazepine receptor and the cardiovascular system. Implications for drug development. Pharmacol. Ther., 2006, 110, 503-524.
18. Veenman, L.; Leschiner, S.; Spanier, I.; Weisinger, G.; Weizman, A.; Gavish, M. PK11195 attenuates kainic acid-induced seizures and alterations in peripheral-type benzodiazepine receptor (PBR) components in the rat brain. J. Neurochem., 2002, 80, 917-927.
19. Galiegue, S.; Tinel, N.; Casellas, P. The peripheral benzodiazepine receptor: a promising therapeutic drug target. Curr. Med. Chem., 2003, 10 (16), 1563-1572.
20. Papadopoulos, V.; Lecanu, L.; Brown, R.C.; Han, Z.; Yao, Z.-X. Peripheral-type benzodiazepine receptor in neurosteroid biosynthesis, neuropathology and neurological disorders. Neurosci., 2006, 138, 749-756.
21. Veenman, L.; Gavish, M., Peripheral-type benzodiazepine receptors: their implication in brain disease. Drug Dev. Res., 2000, 50, 355-370.
22. Pini, S.; Martini, C.; Abelli, M.; Muti, M.; Gesi, C.; Montali, M.; Chelli, B.; Lucacchini, A.; Cassano, G.B. Peripheral-type benzodiazepine receptor binding sites in platelets of patients with panic disorder associated to separation anxiety symptoms. Psycopharmacology (Berl), 2005, 181, 407-411.
23. Chelli, B.; Pini, S.; Abelli, M.; Cardini, A.; Lari, L.; Muti, M.; Gesi, C.; Cassano, G.B.; Lucacchini, A.; Martini, C. Platelet 18 kDa Translocator Protein density is reduced in depressed patients with adult separation anxiety. Eur. Neuropsychopharmacol., 2008, 18, 249-254.
24. Kita, A.; Furukawa, K. Involvement of neurosteroids in the anxiolytic- like effects of AC-5216 in mice. Pharmacol. Biochem. Behav., 2008, 89, 171-178.
25. Dubrovsky, B.O. Steroids, neuroactive steroids and neurosteroids in psychopathology. Prog. Neuro-psychopharmacol. Biol. Psychiatry, 2005, 29, 169-192.
26. Mellon, S.H.; Griffin, L.D. Neurosteroids: biochemistry and clinical significance. Trends Endocrinol. Metab., 2002, 13, 35-43.
27. Strous, R.D.; Maayan, R.; Weizman, A. The relevance of neurosteroids to clinical psychiatry: from the laboratory to the bedside. Eur. Neuropsychopharmacol., 2006, 16, 155-169.
28. A receptors. Trends Neurosci., 2010, 33 (7), 299-306.
29. A receptors. Pharmacol. Ther., 2007, 116, 20-34.
30. Baulieu, E.E.; Robel, P. Neurosteroids: a new brain function? J. Steroid Biochem. Mol. Biol., 1990, 37, 395-403.
31. Baulieu, E.E. Neurosteroids: a novel function of the brain. Psychoneuroendocrinology, 1998, 23, 963-987.
32. A receptors. Prog. Neurobiol., 2003, 71, 67-80.
33. A receptor. Nat. Rev. Neurosci., 2005, 6, 565-575.
34. A receptors. J. Physiol. (Lond.), 2004, 558, 59-74.
35. A receptor. J. Neurosci., 2005, 25, 11605-11613.
36. Kimoto, T.; Tsurugizawa, T.; Ohta, Y.; Makino, J.; Tamura, H-O.; Hojo, Y.; Takata, N.; Kawato, S. Neurosteroid synthesis by cytochrome P450-containing systems localized in the rat brain hippocampal neurons: N-methyl-D-aspartate and calcium-dependent synthesis. Endocrinology, 2001, 142, 3578-3589.
37. King, S.R.; Manna, P.R.; Ishii, T.; Syapin, P.J.; Ginsberg, S.D.; Wilson, K.; Walsh, L.P.; Parker, K.L.; Stocco, D.M.; Smith, R.G.; Lamb, D.J. An essential component in steroid synthesis, the steroidogenic acute regulatory protein, is expressed in discrete regions of the brain. J. Neurosci., 2002, 22, 10613-10620.
38. Agis-Balboa, R.C.; Pinna, G.; Zhubi, A.; Maloku, E.; Veldic, M.; Costa, E.; Guidotti, A. Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis. Proc. Natl. Acad. Sci. USA, 2006, 103, 14602-14607.
39. Rone, M.B.; Fan, J.; Papadopoulos, V. Cholesterol transport in steroid biosynthesis: role of protein-protein interactions and implications in disease states. Biochim. Biophys. Acta, 2009, 1791, 646-658.
40. Bourguignon, J.J. in "Peripheral Benzodiazepine Receptor", Giessen-Crause E. Ed., 58, Academic Press, New York, (1993).
41. Dalpiaz, A.; Bertolasi, V.; Borea, P.A.; Nacci, V.; Fiorini, I.; Campiani, G.; Mennini, T.; Manzoni, C.; Novellino, E.; Greco, G. A concerted study using binding measurements, x-ray structural data, and molecular modeling on the stereochemical features responsible for the affinity of 6-arylpyrrolo[2,1-d][1,5]benzothiazepines toward mitochondrial benzodiazepine receptors. J. Med. Chem., 1995, 38, 4730-4738.
42. 3H]PK11195, by thermodynamic studies. Life Sci., 1983, 33, 449-457.
43. Cappelli, A.; Giuliani, G.; Valenti, S.; Anzini, M.; Vomero, S.; Giorgi, G.; Sogliano, C.; Maciocco, E.; Biggio, G.; Concas, A. Synthesis and structure-activity relationship studies in peripheral benzodiazepine receptor ligands related to alpidem. Bioorg. Med. Chem., 2008, 16, 3428-3437.
44. Parola, A.L.; Stump, O.G.; Pepperl, D.J.; Krueger, K.E.; Regan, J.W.; Laird, H.E. Cloning and expression of a pharmacologically unique bovine peripheral-type benzodiazepine receptor isoquinoline binding protein. J. Biol. Chem., 1991, 266, 14082-14087.
45. Awad, M.; Gavish, M. Binding of [3H]Ro 5-4864 and [3H]PK 11195 to cerebral cortex and peripheral tissues of various species: species differences and heterogeneity in peripheral benzodiazepine binding sites. J. Neurochem., 1987, 49, 1407-1414.
46. Farges, R.; Joseph-Liauzun, E.; Shire, D.; Caput, D.; Le Fur, G.; Ferrara, P. Site-directed mutagenesis of the peripheral benzodiazepine receptor: identification of amino acids implicated in the binding site of Ro5-4864. Mol. Pharmacol., 1994, 46, 1160-1167.
47. James, M.L.; Selleri, S.; Kassiou, M. Development of ligands for peripheral benzodiazepine receptor. Curr. Med. Chem., 2006, 13, 1991-2001.
48. Trapani, G.; Franco, M.; Ricciardi, L.; Latrofa, A.; Genchi, G.; Sanna, E.; Tuveri, F.; Cagetti, E.; Biggio, G.; Liso, G. Synthesis and binding affinity of 2-phenylimidazo[1,2-a]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new series of high-affinity and selective ligands for the peripheral Type. J. Med. Chem., 1997, 40, 3109-3118.
49. Trapani, G.; Franco, M.; Latrofa, A.; Ricciardi, L.; Carotti, A.; Serra, M.; Sanna, E.; Biggio, G.; Liso, G. Novel 2- phenylimidazo[1,2-a]pyridine derivatives as potent and selective ligands for peripheral benzodiazepine receptors: synthesis, binding affinity, and in vivo studies. J. Med. Chem., 1999, 42, 3934-3941.
50. Romeo, E.; Auta, J.; Kozikowski, A.P.; Ma, D.; Papadopoulos, V.; Puia, G.; Costa, E.; Guidotti, A. 2-Aryl-3-indoleacetamides (FGIN- 1): A new class of potent and specific ligands for the mitochondrial DBI receptor (MDR). J. Pharmacol. Exp. Ther., 1992, 262, 971-978.
51. Kozikowski, A.P.; Ma, D.; Brewer, J.; Sun, S.; Costa, E.; Romeo, E.; Guidotti, A. Chemistry, binding affinity, and behavioral properties of a new class of "antineophobic" mitochondrial DBI receptor complex (mDRC) ligands. J. Med. Chem., 1993, 36, 2908-2920.
52. Murata, T.; Masumoto, K.; Kondo, K.; Furukawa, K.; Oka, M. Preparation of 2-aryl-8-oxodihydropurine derivatives as anxiolytics. PCT Int. Appl., WO9928320, 1999.
53. Murata, T.; Kondo, K.; Masumoto, K.; Kohayakawa, H.; Furukawa, K. Preparation of 2-arylpurine-9-acetamide derivatives having selective action on peripheral benzodiazepine receptor, process for the preparation thereof, medicinal compositions containing the same and intermediates of the derivatives. PCT Int. Appl., WO2000073306, 2000.
54. Kita, A.; Kohayakawa, H.; Kinoshita, T.; Ochi, Y.; Nakamichi, K.; Kurumiya, S.; Furukawa, K.; Oka, M. Antianxiety and antidepressant- like effects of AC-5216, a novel mitochondrial benzodiazepine receptor ligand. Br. J. Pharmacol., 2004, 142, 1059-1072.
55. Rupprecht, R.; Rammes, G.; Eser, D.; Baghai, T.C.; Schüle, C.; Nothdurfter, C.; Troxler, T.; Gentsch, C.; Kalkman, H.O.; Chaperon, F.; Uzunov, V.; McAllister, K.H.; Bertaina-Anglade, V.; La Rochelle, C.D.; Tuerk, D.; Floesser, A.; Kiese, B.; Schumacher, M.; Landgraf, R.; Holsboer, F.; Kucher, K. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science, 2009, 325, 490-493.
56. Da Settimo, A.; Primofiore, G.; Da Settimo, F.; Marini, A.M.; Novellino, E.; Greco, G.; Martini, C.; Giannaccini, G.; Lucacchini, A. Synthesis, structure-activity relationships, and molecular modeling studies of N-(Indol-3-ylglyoxylyl)benzylamine derivatives acting at the benzodiazepine receptor. J. Med. Chem., 1996, 39, 5083-5091.
57. Da Settimo, A.; Primofiore, G.; Da Settimo, F.; Marini, A.M.; Novellino, E.; Greco, G.; Gesi, M.; Martini, C.; Giannaccini, G.; Lucacchini, A. N'-Phenylindol-3-ylglyoxylohydrazide derivatives: synthesis, structure-activity relationships, molecular modeling studies, and pharmacological action on brain benzodiazepine receptors. J. Med. Chem., 1998, 41, 3821-3830.
58. Da Settimo, A.; Primofiore, G.; Da Settimo, F.; Bianucci, A.M.; Martini, C.; Senatore, G.; Lucacchini, A.; Synthesis and benzodiazepine receptor affinity of N-(Indol-3-ylglyoxylyl)-dipeptide derivatives. Structural requirements for inverse agonist/antagonist receptor interactions. Drug Des. Discov., 1993, 10, 199-211.
59. Martini, C.; Gervasio, T.; Lucacchini, A.; Da Settimo, A.; Primofiore, G.; Marini, A.M. Specific inhibition of benzodiazepine receptor binding by some N-(Indol-3-ylglyoxylyl)amino acid derivatives. J. Med. Chem., 1985, 28, 506-509.
60. Bianucci, A.M.; Da Settimo, A.; Da Settimo, F.; Primofiore, G.; Martini, C.; Giannaccini, G.; Lucacchini, A. Benzodiazepine receptor affinity and interaction of some N-(Indol-3-ylglyoxylyl)amine derivatives. J. Med. Chem., 1992, 35, 2214-2220.
61. Primofiore, G., Da Settimo, F.; Marini, A.M.; Taliani, S.; La Motta, C.; Simorini, F.; Novellino, E.; Greco, G.; Cosimelli, B.; Ehlardo, M.; Sala, A.; Besnard, F.; Montali, M.; Martini, C. Refinement of the benzodiazepine receptor site topology by structure-activity relationships of new N-(Heteroarylmethyl)indol-3-ylglyoxylamides, J. Med. Chem., 2006, 49, 2489-2495.
62. 2 lipophilic regions of the benzodiazepine receptor site in search for subtype-selective ligands. J. Med. Chem., 2007, 50, 1627-1634.
63. A) γ2 benzodiazepine receptor. J. Med. Chem., 2009, 52, 3723-3734.
64. Primofiore, G.; Da Settimo, F.; Taliani, S.; Simorini, F.; Patrizi, M.P.; Novellino, E.; Greco, G.; Abignente, E.; Costa, B.; Chelli, B.; Martini, C. N,N-Dialkyl-2-phenylindol-3-ylglyoxylamides. A new class of potent and selective ligands at the peripheral benzodiazepine receptor. J. Med. Chem., 2004, 47, 1852-1855.
65. Da Settimo, F.; Simorini, F.; Taliani, S.; La Motta, C.; Marini, A.M.; Salerno, S.; Bellandi, M.; Novellino, E.; Greco, G.; Cosimelli, B.; Da Pozzo, E.; Costa, B.; Simola, N.; Morelli, M.; Martini, C. Anxiolytic-like effects of N,N-dialkyl-2-phenylindol-3- ylglyoxylamides by modulation of translocator protein neurosteroid biosynthesis. J. Med. Chem., 2008, 51, 5798-5806.
66. Houlihan, W.J.; Parrino, V.A.; Uike, Y. Lithiation of N-(2- Alkylphenyl)alkanamides and related compounds. A modified Madelung indole synthesis. J. Org. Chem., 1981, 46, 4511-4515.
67. Fiorini, I.; Nacci, V.; Ciani, S.M.; Garofalo, A.; Campiani, G.; Savini, L.; Novellino, E.; Greco, G.; Bernasconi, P.; Mennini, T. Novel ligands specific for mitochondrial benzodiazepine receptors: 6-arylpyrrolo[2,1-d][1,5]benzothiazepine derivatives. Synthesis, structure-activity relationships, and molecular modeling studies. J. Med. Chem., 1994, 37, 1427-1438.
68. Diaz-Arauzo, H.; Koehler, K.F.; Hagent, T. J.; Cook, J. M. Synthetic and computer assisted analysis of the pharmacophore for agonists at benzodiazepine receptors. Life Sci., 1991, 49, 207-216.
69. Fryer, R.I. Benzodiazepine Ligand-Receptor Interactions. In: The Benzodiazepines, from Molecular Biology to Clinical Practice. Costa, E., Ed; Raven Press: New York, 1983; pp 7-20.
70. Homes, T.P.; Mattner, F.; Keller, P.A.; Katsifis, A. Synthesis and in vitro binding of N,N-dialkyl-2-phenylindol-3-yl-glyoxylamides for the peripheral benzodiazepine binding sites. Bioorg. Med. Chem., 2006, 14, 3938-3946.
71. Campiani, G.; Ramunno, A.; Fiorini, I.; Nacci, V.; Morelli, E.; Novellino, E.; Goegan, M.; Mennini, T.; Sullivan, S.; Zisterer, D.M.; Williams, C.D. Synthesis of new molecular probes for investigation of steroid biosynthesis induced by selective interaction with peripheral type benzodiazepine receptors (PBR). J. Med. Chem., 2002, 45, 4276-4281.
72. Papadopoulos, V.; Mukhin, A.G.; Costa, E.; Krueger, K.E. The peripheral-type benzodiazepine receptor is functionally linked to Leydig cell steroidogenesis. J. Biol. Chem., 1990, 265, 3772-3779.
73. Papadopoulos, V.; Amri, H.; Li, H.; Boujrad, N.; Vidic, B.; Garnier, M. Targeted disruption of the peripheral-type benzodiazepine receptor gene inhibits steroidogenesis in the R2C Leydig tumor cell line. J. Biol. Chem., 1997, 272, 32129-32135.
74. Campiani, G.; Nacci, V.; Fiorini, I.; De Filippis, M.P.; Garofalo, A.; Ciani, S.M.; Greco, G.; Novellino, E.; Williams, D.C.; Zisterer, D.M.; Woods, M.J.; Mihai, C.; Manzoni, C.; Mennini, T. Synthesis, biological activity, SARs of pyrrolobenzoxazepine derivatives, a new class of specific "peripheral-type" benzodiazepine receptor ligands. J. Med. Chem., 1996, 39, 3435-3450.
75. Selleri, S.; Bruni, F.; Costagli, C.; Costanzo, A.; Guerrini, G.; Ciciani, G.; Costa, B.; Martini, C. 2-Arylpyrazolo[1,5-a]pyrimidin- 3-ylacetamides. New potent and selective peripheral benzodiazepine receptor ligands. Bioorg. Med. Chem., 2001, 9, 2661-2671.
76. Selleri, S.; Gratteri, P.; Costagli, C.; Bonaccini, C.; Costanzo, A.; Melani, F.; Guerrini, G.; Ciciani, G.; Costa, B.; Spinetti, F.; Martini, C.; Bruni, F. Insight into 2-phenylpyrazolo[1,5-a]pyrimidin-3- yl acetamides as peripheral benzodiazepine receptor ligands: synthesis, biological evaluation and 3D-QSAR investigation. Bioorg. Med. Chem., 2005, 13, 4821-4834.
77. Rosenkilde, M.M.; Schwartz, T.W. Potency of ligands correlates with affinity measured against agonist and inverse agonists but not against neutral ligand in constitutively active chemokine receptor. Mol. Pharmacol., 2000, 57, 602-609.
78. Walkembach, J.; Bruss, M.; Urban, B.W.; Barann, M. Interactions of metoclopramide and ergotamine with human 5-HT(3A) receptors and human 5-HT reuptake carriers. Br. J. Pharmacol., 2005, 146, 543-552.
79. A receptor activity. Psychoneuroendocrinology, 2011, 36, 463-472.
80. Pellow, S.; Chopin, P.; File, S.E.; Briley, M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods, 1985, 14, 149-167.
81. Dawson, G.R.; Tricklebank, M.D. Use of the elevated plus-maze in the search for novel anxiolytic agents. Trends Pharmacol. Sci., 1995, 16, 33-36.
82. Rodgers, R.J.; Dalvi, A. Anxiety, defence and the elevated plusmaze. Neurosci. Biobehav. Rev., 1997, 21, 801-810.
83. Fabrizi, C.; Colasanti, M.; Persichini, T.; Businaro, R.; Starace, G.; Lauro, G.M. Interferon gamma up-regulates α2 macroglobulin expression in human astrocytoma cells. J. Neuroimmunol., 1994, 53, 31-37.
84. Malorni, W.; Rainaldi, G.; Rivabene, R.; Santini, M.T. Different susceptibilities to cell death induced by t-butylhydroperoxide could depend upon cell histotype-associated growth features. Cell. Biol. Toxicol., 1994, 10, 207-218.
85. Chelli, B.; Salvetti, A.; Da Pozzo, E.; Rechichi, M.; Spinetti, F.; Rossi, L.; Costa, B.; Lena, A.; Rainaldi, G.; Scatena, F.; Vanacore, R.; Gremigni, V., Martini, C. PK11195 differentially affects cell survival in human wild-type and 18 kDa translocator proteinsilenced ADF astrocytoma cells. J. Cell. Biochem., 2008, 105, 712-723.
86. Costa, B.; Pini, S.; Tabelloni, P.; Da Pozzo, E.; Abelli, M.; Lari, L.; Preve, M.; Lucacchini, A.; Cassano, G.B.; Martini, C. The spontaneous Ala147Thr amino acid substitution within the translocator protein influences pregnenolone production in lymphomonocytes of healthy individuals. Endocrinology, 2009, 150, 5438-5445.
87. Krueger, K.E.; Papadopoulos, V. Peripheral-type benzodiazepine receptors mediate translocation of cholesterol from outer to inner mitochondrial membranes in adrenocortical cells. J. Biol. Chem., 1990, 265, 15015-15022.
88. Guarneri, P.; Papadopoulos, V.; Pan, B.; Costa, E. Regulation of pregnenolone synthesis in C6-2B glioma cells by 4'-chlorodiazepam. Proc. Natl. Acad. Sci. USA, 1992, 89, 5118-5122.
89. Genazzani, A.R.; Petraglia, F.; Bernardi, F.; Casarosa, E.; Salvestroni, C.; Tonetti, A.; Nappi, R.E.; Luisi, S.; Palumbo, M.; Purdy, R.H.; Luisi, M. Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences. J. Clin. Endocrinol. Metab., 1998, 83, 2099-2103.
90. Schwartz-Bloom, R.D.; Engblom, A.C.; Akerman, K.E.; Inglefield, J.R. Measurement of chloride movement in neuronal preparations. Curr. Protoc. Neurosci., 2001, 10, Chapter 7: Unit 7.10
91. - channels by zinc in adult rat brain: a regional study. Neurochem. Res., 1996, 21, 955-961.
92. Dall'Osso, L.; Da Pozzo, E.; Carmassi, C.; Trincavelli, M.L.; Ciapparelli, A.; Martini, C. Lifetime manic-hypomanic symptoms in post-traumatic stress disorder: relationship with the 18 kDa mitochondrial translocator protein density. Psychiatry Res., 2010, 177, 139-143.
93. Laquintana, V.; Denora, N.; Lopedota, A.; Suzuki, H.; Sawada, M.; Serra, M.; Biggio, G.; Latrofa, A.; Trapani, G.; Liso, G. N-Benzyl- 2-(6,8-dichloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)-N- (6-(7-nitrobenzo[c][1,2,5]oxadiazol-4-ylamino)hexyl)acetamide as a new fluorescent probe for peripheral benzodiazepine receptor and microglial cell visualization. Bioconjugate Chem., 2007, 18, 1397-1407.
94. Taliani, S.; Simorini, F.; Sergianni, V.; La Motta, C.; Da Settimo, F.; Cosimelli, B.; Abignente, E.; Greco, G.; Novellino, E.; Rossi, L.; Gremigni, V.; Spinetti, F.; Chelli, B.; Martini, C. New fluorescent 2-phenylindolglyoxylamide derivatives as probes targeting the peripheral-type benzodiazepine receptor: design, synthesis, and biological evaluation. J. Med. Chem., 2007, 50, 404-407.
95. Newman, A.H. Irreversible ligands as probes for drugs receptors. NIDA Res. Monogr., 1991, 112, 256-283.
96. Taliani, S.; Da Pozzo, E.; Bellandi, M.; Bendinelli, S.; Pugliesi, I.; Simorini, F.; La Motta, C.; Salerno, S.; Marini, A.M.; Da Settimo, F.; Cosimelli, B.; Greco, G.; Novellino, E.; Martini, C. Novel irreversible fluorescent probes targeting the 18 kDa translocator protein: synthesis and biological characterization. J. Med. Chem., 2010, 53, 4085-4093.
97. Schweitzer, P.J.; Fallon, B.A.; Mann, J.J.; Kumar, J.S.D. PET tracers for the peripheral benzodiazepine receptor and uses thereof. Drug Discov. Today, 2010, 15, 933-942.
98. Dollé, F.; Luus, C.; Reynolds, A.; Kassiou, M. Radiolabelled molecules for imaging the translocator protein (18 kDa) using positron emission tomography. Curr. Med. Chem., 2009, 16, 2899-2923.
99. Chaveau, F.; Boutin, H.; Van Camp, N.; Dollé, F.; Tavitian, B. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 2304-2319.
100. 1-Methyl-2-phenylindol-3-ylglyoxylamides as a new chemotype of 18 kDa translocator protein-selective ligand suitable for the development of positron emission tomography radioligands. J. Med. Chem., 2011, 54, 366-373.
101. Venneti, S.; Lopresti, B.J.; Wiley, C.A. The peripheral benzodiazepine receptor (translocator protein 18 kDa) in microglia: from pathology to imaging. Prog. Neurobiol., 2006, 80, 308.
102. 11C) methyl, N- (methyl-1-propyl), (chloro-2-phenyl)-1 isoquinoleine carboxamide- 3 (PK 11195): A new ligand for peripheral benzodiazepine receptors. J. Label Compd. Radiopharm., 1984, 21, 985-991.
103. Luus, C.; Hanani, R.; Reynolds, A.; Kassiou, M. The development of PET radioligands for imaging the translocator protein (18 kDa): What have we learned? J. Label Compd. Radiopharm, 2010, 53, 501-510.
104. Uppoor, R.S.; Mummaneni, P.; Cooper, E.; Pien, H.H., Sorensen, A.G.; Collins, J.; Mehta, M.U., Yasuda, S.U. The use of imaging in the early development of neuropharmacological drugs: a survey of approved NDAs. Clin. Pharmacol. Ther., 2008, 84, 69-74.
105. Owen, D.R.J.; Gunn, R.N.; Rabiner, E.A.; Bennacef, I.; Fujita, M.; Kreisl, W.C.; Innis, R.B.; Pike, V.W.; Reynolds, R.; Matthews, P.M.; Parker, K.A. Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J. Nuclear Medicine, 2010, 52, 24-32.
106. Owen, D.R.J.; Lewis, A.J.M.; Reynolds R.; Rupprecht, R.; Eser, D.; Wilkins M.R., Bennacef, I.; Nutt, D.J.; Parker, C.A. Variation in binding affinity of the novel anxiolytic XBD173 for the 18 kDa translocator protein in human brain. Synapse, 2011, 65, 257-259.
107. Imaizumi, M.; Briard, E.; Zoghbi, S.S.; Gourley, J.P.; Hong, J.; Musachio J.L.; Gladding, R.; Pike, V.W.; Innis, R.B.; Fujita, M. Kinetic evaluation in nonhuman primates of two new PET ligands for peripheral benzodiazepine receptor in brain. Synapse, 2007, 61, 595-605.